Flow Diverter Versus Conventional Endovascular Treatment for Unruptured Wide-Neck Bifurcation Aneurysms (FD-BWA Trial)

Inclusion criteria

• Age 18-75 years;
• Diagnosis of unruptured intracranial, bifurcation, saccular, wide-neck aneurysm by DSA/CTA/MRA;
• Patients who can understand the purpose of the trial, voluntarily participate and sign the informed consent form.

Exclusion criteria

• Patients with two or more multiple aneurysms that all require treatment within 1 year;
• Concomitant cerebrovascular diseases such as arteriovenous malformation, moyamoya disease;
• Ruptured aneurysms and narrow-neck aneurysms;
• Patients who have had a stroke (cerebral hemorrhage, cerebral infarction) within the past 1 month;
• Extremely poor clinical condition, modified Rankin Score ≥3;
• Patients already scheduled for surgery/interventional procedure within 3 months;
• Patients deemed unsuitable for interventional treatment by the investigator (e.g., no suitable vascular access, excessively tortuous vessels, difficulty delivering stent);
• Patients unsuitable for anesthesia or endovascular surgery, such as major diseases of heart, lung, liver, spleen, kidney, brain tumors, severe active infections, disseminated intravascular coagulation, severe mental illness;
• Patients unable to receive antiplatelet or anticoagulant therapy;
• Patients who have had or may have severe reactions to contrast media precluding pre-treatment medication;
• Patients with a definite history of allergy to cobalt-chromium, nickel-titanium alloy materials;
• Participation in other drug or medical device clinical trials before enrollment without reaching the primary endpoint timeframe;
• Pregnant or breastfeeding women;
• Patient's life expectancy less than 12 months;
• Investigator judges that the patient has poor compliance and cannot complete the study as required.